RT Journal Article
SR Electronic
T1 Nicotinamide: A Key Player in the Developmental Origins of Parkinson’s Disease? (I1.001)
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP I1.001
VO 86
IS 16 Supplement
A1 Williams, Adrian
A1 Griffin, Síle
A1 Pickard, Mark
A1 Fricker, Rosemary
YR 2016
UL http://n.neurology.org/content/86/16_Supplement/I1.001.abstract
AB OBJECTIVE: To investigate the role of vitamin B3 (nicotinamide) on midbrain dopaminergic neuron development. BACKGROUND: The active forms of vitamins A & C are linked to optimal development of neurons . Little is known regarding the role of vitamin B3 even though poor cognitive development and parkinsonism were features of pellagra . DESIGN/METHODS: Monolayer mouse embryonic stem cell cultures (mESC; Sox1GFP knock-in 46C cell line) were treated with nicotinamide for different durations and immunocytochemistry/ fluorescence microscopy was performed to assess the expression of stem cell, neural progenitor (NP) and neuronal subtype markers. RESULTS: Nicotinamide accelerated the conversion process of mESCs to neurons with a catecholaminergic phenotype. Specifically, the proportion of proliferating cells was significantly reduced in nicotinamide-treated cultures - that is, nicotinamide regulates the proliferation-to-differentiation switch from NPs to neurons during development. Nicotinamide drives dopamine neuron differentiation (10mM) as effectively as known cocktails of signalling factors, and acts in a dose-dependent manner in a defined time-window - with high doses (20mM) however causing toxicity. CONCLUSIONS: Nicotinamide aids the conversion of stem cells to dopaminergic neurons increasing efficiency and safety of the cells produced, and reducing cost; important as we progress towards patient-specific cell replacement therapy for Parkinson’s . Our data also suggest that nicotinamide is a key signalling factor required in a definable dosage range at key times for the formation of a healthy population of dopamine neurons. An optimal maternal to foetal dietary dosage of nicotinamide - neither too low nor too high - could be linked to Parkinson’s disease later in life.Disclosure: Dr. Williams has nothing to disclose. Dr. Griffin has nothing to disclose. Dr. Pickard has nothing to disclose. Dr. Fricker has nothing to disclose.Saturday, April 16 2016, 1:00 pm-5:30 pm